CO5280046A1 - Agonistas alfa 7 y sus composiciones farmaceuticas - Google Patents
Agonistas alfa 7 y sus composiciones farmaceuticasInfo
- Publication number
- CO5280046A1 CO5280046A1 CO01012482A CO01012482A CO5280046A1 CO 5280046 A1 CO5280046 A1 CO 5280046A1 CO 01012482 A CO01012482 A CO 01012482A CO 01012482 A CO01012482 A CO 01012482A CO 5280046 A1 CO5280046 A1 CO 5280046A1
- Authority
- CO
- Colombia
- Prior art keywords
- oxygen
- sulfur
- jpeg
- mfi
- sulfur atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Un compuesto de fórmula I<EMI FILE="01012482_1" ID="1" IMF=JPEG > dondeA es<EMI FILE="01012482_2" ID="2" IMF=JPEG >D es oxígeno o azufre,E es un enlace simple, oxígeno, azufre, o NR10;R es hidrógeno o metil;Ar1 es un anillo aromático o heteroaromático de 5 o 6 miembros que contiene 0, 1, 2 o 3 átomos de nitrógeno, oxígeno o azufre, donde no hay más de 1 átomo de oxígeno o azufre;Ar2 es un anillo aromático o heteroaromático de 5 o 6 miembros que contiene 0, 1, 2, o 3 átomos de nitrógeno, oxígeno o azufre, donde no hay mas de 2 átomos de oxígeno o azufre;o un sistema de anillos aromáticos o heteroaromáticos de 8, 9 o 10 miembros fusionados que contiene 0, 1, 2 o 3 átomos de nitrógeno, oxígeno o azufre, donde no hay más de 2 átomos de oxígeno o azufre;en donde si Ar2 es fenil no substituido, Ar1 no es pirazolil;donde los anillos aromáticos Ar1 y Ar2 son substituidos con 0, 1, 2 o 3 substituyentes seleccionados entre: halógeno, alquil C1-4, alquenil C2-4, alquinil C2-4, CN, NO2, NR1R2, CH2NR1R2, OR3, CH2OR3, CO2R4, y CF3;pero si Ar1 es fenil y Ar2 es quinolinil, entonces Ar2 es substituido con 0, 1, 2 o 3 subslituyentes seleccionados entre alquil C1-4, alquenil C2-4, alquinil C2-4, CN, NO2, NR1R2, CH2NR1R2, OR3, CH2OR3 y CO2R4; R1 R2 y R3 son independientemente alquil C1-4, aril, - 2 - heteroaril, C(O)R5, C(O)NHR6, C(O)R7 SO2R8 o R1 y R2 pueden ser juntos (CH2)jG(CH2)k donde G es oxigeno, azufre, NR9, o un enlace simple;j es 2, 3 o 4;k es 0, 1 o 2,R4, R5, R6, R7, R8, R9, y R10, son independientemente alquil C1-4, aril, o,heteroaril, o un enantiómero del mismo, y sales farmacéuticamente aceptables del mismo, con la condición que:(1) si D representa oxígeno, E representa un enlace simple, y A representa <EMI FILE="01012482_3" ID="3" IMF=JPEG >y si Ar1 o Ar2 representa un anillo pirazol, entonces todos los sustituyentes opcionales en el anillo pirazol son hidrógeno; y(2) si Ar1 representa un anillo piridina, Ar2 representa un anillo arilo, y A representa <EMI FILE="01012482_4" ID="4" IMF=JPEG >luego todos los substituyentes opcionales en el anillo piridina serán hidrógeno; y(3) la fórmula I no representa:<EMI FILE="01012482_5" ID="5" IMF=JPEG >
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0000540A SE0000540D0 (sv) | 2000-02-18 | 2000-02-18 | New compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5280046A1 true CO5280046A1 (es) | 2003-05-30 |
Family
ID=20278508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO01012482A CO5280046A1 (es) | 2000-02-18 | 2001-02-16 | Agonistas alfa 7 y sus composiciones farmaceuticas |
Country Status (34)
Country | Link |
---|---|
US (3) | US7001914B2 (es) |
EP (1) | EP1259508B1 (es) |
JP (1) | JP4084570B2 (es) |
KR (1) | KR100769394B1 (es) |
CN (1) | CN100345847C (es) |
AR (1) | AR029798A1 (es) |
AT (1) | ATE252099T1 (es) |
AU (1) | AU782693B2 (es) |
BG (1) | BG106977A (es) |
BR (1) | BR0108456A (es) |
CA (1) | CA2397233A1 (es) |
CO (1) | CO5280046A1 (es) |
CZ (1) | CZ20022787A3 (es) |
DE (1) | DE60100996T2 (es) |
DK (1) | DK1259508T3 (es) |
EE (1) | EE05149B1 (es) |
ES (1) | ES2208556T3 (es) |
HK (1) | HK1050007A1 (es) |
HU (1) | HUP0301069A3 (es) |
IL (1) | IL150544A0 (es) |
IS (1) | IS6492A (es) |
MX (1) | MXPA02007543A (es) |
MY (1) | MY123580A (es) |
NO (1) | NO20023917L (es) |
NZ (1) | NZ520094A (es) |
PL (1) | PL202044B1 (es) |
PT (1) | PT1259508E (es) |
RU (1) | RU2263114C2 (es) |
SE (1) | SE0000540D0 (es) |
SK (1) | SK11792002A3 (es) |
TR (1) | TR200400072T4 (es) |
UA (1) | UA73540C2 (es) |
WO (1) | WO2001060821A1 (es) |
ZA (1) | ZA200205479B (es) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0000540D0 (sv) * | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
EP1381603A2 (en) | 2000-08-18 | 2004-01-21 | PHARMACIA & UPJOHN COMPANY | Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands ) |
US6492385B2 (en) | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
WO2002016357A2 (en) * | 2000-08-18 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
US6492386B2 (en) * | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
EP1311505A2 (en) * | 2000-08-21 | 2003-05-21 | PHARMACIA & UPJOHN COMPANY | Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands ) |
AU2001282875A1 (en) | 2000-08-21 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
PE20021019A1 (es) * | 2001-04-19 | 2002-11-13 | Upjohn Co | Grupos azabiciclicos sustituidos |
AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
AR036041A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen |
WO2003018585A1 (en) | 2001-08-24 | 2003-03-06 | Pharmacia & Upjohn Company | Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease |
EP1425286B1 (en) * | 2001-09-12 | 2007-02-28 | Pharmacia & Upjohn Company LLC | Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases |
CZ2004408A3 (cs) | 2001-10-02 | 2005-03-16 | Pharmacia & Upjohn Company | Azabicyklicky substituované kondenzované heteroarylsloučeniny |
EP1453828A2 (en) * | 2001-10-16 | 2004-09-08 | AstraZeneca AB | Azabicyclic compounds for the treatment of fibromyalgia syndrome |
US6849620B2 (en) | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
MXPA04003986A (es) * | 2001-10-26 | 2004-07-23 | Upjohn Co | Carboxamidas hetero-biciclicas n-azabiciclico sustituidas como agonistas nachr. |
US6919359B2 (en) | 2001-11-08 | 2005-07-19 | Pfizer Inc | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease |
BR0214016A (pt) | 2001-11-09 | 2004-10-13 | Upjohn Co | Compostos azabicìclico-fenil-fundido heterocìclicos e seu uso como ligandos alfa 7 nachr |
DE10156719A1 (de) * | 2001-11-19 | 2003-05-28 | Bayer Ag | Heteroarylcarbonsäureamide |
DE10162375A1 (de) | 2001-12-19 | 2003-07-10 | Bayer Ag | Bicyclische N-Aryl-amide |
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
EP1480977A2 (en) | 2002-02-15 | 2004-12-01 | PHARMACIA & UPJOHN COMPANY | Substituted aryl compounds for treatment of disease |
MXPA04008038A (es) | 2002-02-19 | 2004-11-26 | Upjohn Co | Carboxamidas heteroaromaticas biciclicas condensadas con puente de n para el tratamiento de enfermedades. |
CA2476624A1 (en) | 2002-02-19 | 2003-08-28 | Pharmacia & Upjohn Company | Azabicyclic compounds for the treatment of disease |
DE10211416A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Essig- und Propionsäureamide |
DE10211415A1 (de) * | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
JP4542891B2 (ja) * | 2002-06-10 | 2010-09-15 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 2−ヘテロアリールカルボキサミド類 |
WO2004013137A1 (en) | 2002-08-01 | 2004-02-12 | Pharmacia & Upjohn Company Llc | 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity |
GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
PL377777A1 (pl) * | 2002-12-11 | 2006-02-20 | Pharmacia & Upjohn Company Llc | Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków |
KR20050092777A (ko) * | 2003-01-22 | 2005-09-22 | 파마시아 앤드 업존 캄파니 엘엘씨 | 알파-7 nACh 수용체 전체 작용물질을 사용하는 질병의치료 |
GB0310867D0 (en) * | 2003-05-12 | 2003-06-18 | Novartis Ag | Organic compounds |
US20050129610A1 (en) * | 2003-06-24 | 2005-06-16 | Johns Hopkins University | Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor |
DE10334724A1 (de) * | 2003-07-30 | 2005-02-24 | Bayer Healthcare Ag | N-Biarylamide |
CN1914200A (zh) * | 2003-12-22 | 2007-02-14 | 阿斯利康(瑞典)有限公司 | 烟碱性乙酰胆碱受体配件 |
JP2007515478A (ja) * | 2003-12-22 | 2007-06-14 | アストラゼネカ・アクチエボラーグ | ニコチン性アセチルコリンレセプターリガンド |
PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
GB0424564D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
WO2007001225A1 (en) * | 2005-06-29 | 2007-01-04 | Astrazeneca | Thiophene-2-carboxamide derivatives as alpha 7 nicotinic receptor modulators. |
GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
JP4827986B2 (ja) | 2007-06-08 | 2011-11-30 | マンカインド コーポレ−ション | IRE−1αインヒビター |
TW200911808A (en) * | 2007-07-23 | 2009-03-16 | Astrazeneca Ab | Novel compounds |
SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
BR112012008518A2 (pt) | 2009-10-13 | 2016-04-05 | Msd Oss Bv | derivado heterocíclico, e, composição farmacêutica |
JP5749797B2 (ja) | 2010-05-17 | 2015-07-15 | フォルム ファーマシューティカルズ、インコーポレイテッド | (r)−7−クロロ−n−(キヌクリジン−3−イル)ベンゾ[b]チオフェン−2−カルボキサミド塩酸塩一水和物の結晶形 |
KR101928505B1 (ko) * | 2011-01-28 | 2018-12-12 | 에스케이바이오팜 주식회사 | 피리돈 유도체 및 이를 포함하는 약학적 조성물 |
KR101925971B1 (ko) * | 2011-01-28 | 2018-12-06 | 에스케이바이오팜 주식회사 | 피리돈 유도체 및 이를 포함하는 약학적 조성물 |
GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
TWI589576B (zh) | 2011-07-15 | 2017-07-01 | 諾華公司 | 氮雜-雙環二芳基醚之鹽類及製造彼等或其前驅物之方法 |
JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
WO2013169646A1 (en) | 2012-05-08 | 2013-11-14 | Envivo Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
CN105189482A (zh) | 2013-02-07 | 2015-12-23 | 武田药品工业株式会社 | 作为毒蕈碱m4受体激动剂的哌啶-1-基羧酸酯和氮杂卓-1-基羧酸酯 |
AU2014282977B2 (en) | 2013-06-21 | 2018-06-14 | Takeda Pharmaceutical Company Limited | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors |
GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
FI20145054L (fi) * | 2014-01-21 | 2015-07-22 | Tellabs Oy | Tiedonsiirtoverkon verkkoelementti |
TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
KR101623138B1 (ko) | 2014-10-28 | 2016-05-20 | 한국원자력연구원 | 베타 아밀로이드 플라크 검출 및 알츠하이머 질환 진단 또는 치료용 조성물 |
GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1416872A (en) * | 1972-03-10 | 1975-12-10 | Wyeth John & Brother Ltd | 4-aminoquinoline derivatives |
FI791491A (fi) * | 1979-05-10 | 1980-11-11 | Kopo Konepohja Oy | Traebitshugg |
FR2529548A1 (fr) * | 1982-07-02 | 1984-01-06 | Delalande Sa | Nouveaux derives de l'amino-3 quinuclidine, leur procede et leur application en therapeutique |
US4605652A (en) * | 1985-02-04 | 1986-08-12 | A. H. Robins Company, Inc. | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes |
US4863919A (en) * | 1988-02-01 | 1989-09-05 | A. H. Robins Company, Incorporated | Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes |
US5342845A (en) * | 1990-08-31 | 1994-08-30 | Nippon Shinyaku Company Limited | Indole derivatives and drugs |
JPH04247081A (ja) * | 1991-02-01 | 1992-09-03 | Takeda Chem Ind Ltd | 5員複素環酸アミド類 |
SE9904176D0 (sv) | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
SE0000540D0 (sv) * | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
FR2809730B1 (fr) | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo[3.2.2] nonanebenzoxazole, -benzothiazole et -benzimidazole, leur preparation et leur application therapeutique |
FR2809731B1 (fr) | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo-[3.2.2] nonane-pheylisoxazole, leur preparation et leur application en therapeutique |
FR2809732B1 (fr) | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE |
TW593223B (en) | 2000-06-20 | 2004-06-21 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists |
US6492385B2 (en) * | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
EP1381603A2 (en) | 2000-08-18 | 2004-01-21 | PHARMACIA & UPJOHN COMPANY | Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands ) |
WO2002016357A2 (en) | 2000-08-18 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
US6492386B2 (en) | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
EP1311505A2 (en) | 2000-08-21 | 2003-05-21 | PHARMACIA & UPJOHN COMPANY | Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands ) |
AU2001282875A1 (en) | 2000-08-21 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
AU2002220517A1 (en) | 2000-12-01 | 2002-06-11 | Neurosearch A/S | 3-substituted quinuclidines and their use as nicotinic agonists |
US20020086871A1 (en) | 2000-12-29 | 2002-07-04 | O'neill Brian Thomas | Pharmaceutical composition for the treatment of CNS and other disorders |
CN1914200A (zh) * | 2003-12-22 | 2007-02-14 | 阿斯利康(瑞典)有限公司 | 烟碱性乙酰胆碱受体配件 |
US7396830B2 (en) * | 2005-10-04 | 2008-07-08 | Bristol-Myers Squibb Company | Piperazine amidines as antiviral agents |
-
2000
- 2000-02-18 SE SE0000540A patent/SE0000540D0/xx unknown
-
2001
- 2001-02-12 AR ARP010100628A patent/AR029798A1/es unknown
- 2001-02-15 IL IL15054401A patent/IL150544A0/xx unknown
- 2001-02-15 JP JP2001560205A patent/JP4084570B2/ja not_active Expired - Fee Related
- 2001-02-15 DE DE60100996T patent/DE60100996T2/de not_active Expired - Fee Related
- 2001-02-15 RU RU2002118302/04A patent/RU2263114C2/ru active
- 2001-02-15 AU AU32594/01A patent/AU782693B2/en not_active Ceased
- 2001-02-15 CZ CZ20022787A patent/CZ20022787A3/cs unknown
- 2001-02-15 UA UA2002075475A patent/UA73540C2/uk unknown
- 2001-02-15 PL PL357565A patent/PL202044B1/pl not_active IP Right Cessation
- 2001-02-15 DK DK01904770T patent/DK1259508T3/da active
- 2001-02-15 SK SK1179-2002A patent/SK11792002A3/sk unknown
- 2001-02-15 EE EEP200200459A patent/EE05149B1/xx not_active IP Right Cessation
- 2001-02-15 HU HU0301069A patent/HUP0301069A3/hu unknown
- 2001-02-15 ES ES01904770T patent/ES2208556T3/es not_active Expired - Lifetime
- 2001-02-15 CN CNB018049362A patent/CN100345847C/zh not_active Expired - Fee Related
- 2001-02-15 EP EP01904770A patent/EP1259508B1/en not_active Expired - Lifetime
- 2001-02-15 WO PCT/SE2001/000329 patent/WO2001060821A1/en active IP Right Grant
- 2001-02-15 AT AT01904770T patent/ATE252099T1/de not_active IP Right Cessation
- 2001-02-15 NZ NZ520094A patent/NZ520094A/en unknown
- 2001-02-15 BR BR0108456-9A patent/BR0108456A/pt not_active Application Discontinuation
- 2001-02-15 PT PT01904770T patent/PT1259508E/pt unknown
- 2001-02-15 TR TR2004/00072T patent/TR200400072T4/xx unknown
- 2001-02-15 KR KR1020027010731A patent/KR100769394B1/ko not_active IP Right Cessation
- 2001-02-15 CA CA002397233A patent/CA2397233A1/en not_active Abandoned
- 2001-02-15 MX MXPA02007543A patent/MXPA02007543A/es active IP Right Grant
- 2001-02-16 MY MYPI20010711A patent/MY123580A/en unknown
- 2001-02-16 CO CO01012482A patent/CO5280046A1/es not_active Application Discontinuation
-
2002
- 2002-04-15 US US10/123,856 patent/US7001914B2/en not_active Expired - Fee Related
- 2002-07-09 ZA ZA200205479A patent/ZA200205479B/xx unknown
- 2002-08-02 BG BG106977A patent/BG106977A/bg unknown
- 2002-08-08 IS IS6492A patent/IS6492A/is unknown
- 2002-08-16 NO NO20023917A patent/NO20023917L/no not_active Application Discontinuation
-
2003
- 2003-03-28 HK HK03102250A patent/HK1050007A1/xx not_active IP Right Cessation
-
2006
- 2006-01-05 US US11/325,787 patent/US7214688B2/en not_active Expired - Fee Related
-
2007
- 2007-03-01 US US11/680,930 patent/US7491734B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5280046A1 (es) | Agonistas alfa 7 y sus composiciones farmaceuticas | |
CO5280079A1 (es) | Nuevos compuestos | |
CO5261607A1 (es) | Nuevo uso | |
CO5590895A2 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos | |
EA200100428A1 (ru) | Производные тетрагидробензазепина, полезные в качестве модуляторов допаминовых d3 рецепторов (антипсихотические агенты) | |
DE69304057D1 (de) | Indole fungizide | |
AR025975A1 (es) | Compuestos quimicos. | |
AR007077A1 (es) | Derivados tetrahidroisoquinolina, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, el uso de los mismos parala fabricacion de un medicamento | |
CO4970713A1 (es) | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen | |
ATE366249T1 (de) | Zyklische amid-derivate | |
ES2188280T3 (es) | Acetales heteroaril-ciclicos. | |
CO5690588A2 (es) | Derivados de 4-tetrazolilo-4 fenilpiperidina para el trata- miento del dolor | |
CY1107677T1 (el) | Παραγωγα της 1-[indol-3-yl)carbonyl]piperazine | |
ES2148170T3 (es) | Derivados de xantina. | |
CO5251458A1 (es) | Nuevos compuestos | |
HRP20090147T3 (en) | Pharmaceutical formulation comprising a pyrimidine-a-one derivative coated with an enteric polymer | |
HUP0201357A2 (hu) | Aszimmetrikus rézkomplex, előállítása, és eljárás ciklopropánkarbonsav-észter-származékok előállítására felhasználásával | |
GR1002281B (el) | Παραγωγα 3(2η)-πυριδαζινονης και μεθοδος για την παρασκευη τους. | |
CO5221057A1 (es) | Componentes y composiciones plagicidas | |
NO912298D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksanderivater. | |
CO5160261A1 (es) | Derivados de bifenilo sustituidos que son antagonistas nk-1, su procedimiento de sintesis y composiciones farmaceuticas que los contienen | |
ES2087729T3 (es) | Derivados de 2-amino-1,2,3,4-tetrahidronaftaleno activos sobre el sistema cardiovascular, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. | |
AR016416A1 (es) | Fenil-alquil-imidazoles, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de un medicamento | |
CO5290257A1 (es) | Nuevos derivados de fenilheteroalquilamina, procesos para su preparacion, composiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia | |
DE69928951D1 (de) | 2,3-dihydro-1h-isoindol-derivate verwendbar als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |